Ingenza Begin Working to The Principles of cGMP

In May 2010 work commenced in Ingenza Ltd’s first cGMP compatible laboratory. The laboratory, complete with state-of-the-art equipment, is the fourth addition to Ingenza’s already fully functional Biotechnology, Process Development and Fermentation laboratories.

Ingenza are implementing The Principles of cGMP (Current Good Manufacturing Practice) within the company to extend into the rapidly growing biopharmaceutical market and attract new customers. Many new active pharmaceutical ingredients are biopharmaceuticals such as clinically beneficial antibodies or enzymes. Biopharmaceuticals are being introduced by drug companies to treat a range of diseases such as cancers and arthritis. Ingenza’s work in biopharmaceuticals builds on core skills in strain engineering, molecular biology and downstream processing to deliver improved manufacturing of these high value products. cGMP compatibility requires thorough documentation and full traceability of all processes to ensure that the development work performed at Ingenza can be readily scaled up into full cGMP manufacture.

Dr. Alison Frew, Head of Quality at Ingenza explains, “The past few months have been a very exciting time for Ingenza with the launch of our cGMP compatible laboratory. It has been a lot of hard work to go from an empty shell to a fully equipped laboratory complete with all of the required documentation but with great team support it has been possible.” Dr. Frew continued, “We now look forward with enthusiasm to the new opportunities available to Ingenza through the opening of this laboratory.”

Ingenza has a developed customer base in biopharmaceuticals; the upgrade to cGMP compatibility will attract significant new business from a wider range of biopharmaceutical companies.

For more information please visit the Ingenza website: www.ingenza.com